Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association Between Insulin-like Growth Factor-2 Expression and Prognosis after Transcatheter Arterial Chemoembolization and Octreotide in Patients with Hepatocellar Carcinoma

  • Xiong, Zheng-Ping (Department of Interventional Radiology, Hunan Provincial Tumor Hospital, Central South University) ;
  • Huang, Fang (Department of Infection, The Third XiangYa Hospital, Central South University) ;
  • Lu, Meng-Hou (Department of Infection, Xiang Ya Hospital, Central South University)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: To investigate the association between the change of IGF-2 level in serum after transcatheter arterial chemoembolization (TACE) and hepatocellular carcinoma (HCC) progression, especially in relation to metastasis. Methods: IGF-2 in serum was measured by quantitative sandwich enzyme-linked immunosorbent assaybefore, 3 days and 4 weeks after TACE in 60 patients with HCC. The occurrence of HCC metastasis was also evaluated, 3 months after TACE. Results: (1) The average serum level of IGF-2 in the 60 patients with HCC was $136.5{\pm}87.3$ pg/ml; (2) A tendency for increase was observed with heterogenous uptake of octreotide and portal vein thrombosis. Metastatic foci were found in 37/38 patients in the group with IGF-2 increasing (97.0%), in contrast to 3/22 (13.6%) patients with IGF-2 decrease. Conclusion: The increase of IGF-2 level in serum appears to be associated with the occurrence of metastatic HCC after TACE and chemotherapy.

Keywords

References

  1. Bao Y, Feng WM, Tang CW, et al (2012). Endostatin Inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization. Hepatogastroenterology, 28, 59.
  2. Barbare JC, Bouche O, Bonnetain F, et al (2009). Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer, 45, 1788-97. https://doi.org/10.1016/j.ejca.2009.02.018
  3. El Tayebi HM, Salah W, El Sayed IH, et al (2011). Expression of insulin-like growth factor-II, matrix metalloproteinases, and their tissue inhibitors as predictive markers in the peripheral blood of HCC patients. Biomarkers, 16, 346-54. https://doi.org/10.3109/1354750X.2011.573095
  4. Facciorusso A, Nacchiero MC, Rosania R, et al (2012). Pathways and gene expression profiles in hepatocellular carcinoma. Minerva Gastroenterol Dietol, 58, 35-48.
  5. Finn RS (2012). Advanced HCC: emerging molecular therapies. Minerva Gastroenterol Dietol, 58, 25-34.
  6. Guo TK, Hao XY, Ma B, et al (2009). Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol, 135, 1685-92. https://doi.org/10.1007/s00432-009-0615-3
  7. Hasskarl J, Kaufmann M, Schmid HA (2011). Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. Future Oncol, 7, 895-913. https://doi.org/10.2217/fon.11.66
  8. Jiang J, Deng L, He L, et al (2011). Expression, purification, refolding, and characterization of octreotide-interleukin-2: a chimeric tumor-targeting protein. Int J Mol Med, 28, 549-56.
  9. Ji XQ, Ruan XJ, Chen H, et al (2011). Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit, 17, 169-76.
  10. Laznicek M, Laznickova A, Maecke HR (2012). Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs. Anticancer Res, 32, 761-6.
  11. Niu J, Su Z, Xiao Y, et al (2012).Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery. Eur J Pharm Sci, 45, 216-26. https://doi.org/10.1016/j.ejps.2011.11.013
  12. Prete SD, Montella L, Caraglia M, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol, 66, 837-44. https://doi.org/10.1007/s00280-009-1226-z
  13. Qian J, Yao D, Dong Z, et al (2010). Characteristics of hepatic igf-ii expression and monitored levels of circulating igf-ii mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol, 134, 799-806. https://doi.org/10.1309/AJCPTFDSE2V3LCZP
  14. Rehem RN, El-Shikh WM (2011). Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology, 58, 949-54.
  15. Salvatore DP, Liliana M, Michele C, et al (2010). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So. LAR. study. Cancer Chemother Pharmacol, 66, 837-44. https://doi.org/10.1007/s00280-009-1226-z
  16. Wachter DL, Kristiansen G, Soll C, et al (2012). Insulin-like growth factor II mRNA-binding protein 3 (IMP3) expression in hepatocellular carcinoma. A clinicopathological analysis with emphasis on diagnostic value. Histopathology, 60, 278-86. https://doi.org/10.1111/j.1365-2559.2011.04091.x
  17. Wang Z, Zhou J, Fan J, et al (2009). Sirolimus inhibits the growth and metastatic progression of hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 135, 715-22. https://doi.org/10.1007/s00432-008-0506-z
  18. Xiang ZL, Zeng ZC, Fan J, et al (2011). Gene expression profiling of fixed tissues identified hypoxia-inducible factor-$1\alpha$, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res, 17, 5463-72. https://doi.org/10.1158/1078-0432.CCR-10-3096
  19. Zhang Y, Zhang H, Wang X, et al (2012). The eradication of breast cancer and cancer stem cells using octreotide modified paclitaxel active targeting micelles and salinomycin passive targeting micelles. Biomaterials, 33, 679-91. https://doi.org/10.1016/j.biomaterials.2011.09.072

Cited by

  1. Lack of any Prognostic Role of Insulin-Like Growth Factor-1 Receptor in Non-Small Cell Lung Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5753
  2. Role of Hyperinsulinemia in Increased Risk of Prostate Cancer: A Case Control Study from Kathmandu Valley vol.15, pp.2, 2014, https://doi.org/10.7314/APJCP.2014.15.2.1031
  3. Drainage Alone or Combined with Anti-tumor Therapy for Treatment of Obstructive Jaundice Caused by Recurrence and Metastasis after Primary Tumor Resection vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2681
  4. Multimodality Therapy and Liver Transplantation for Hepatocellular Carcinoma vol.98, pp.1, 2014, https://doi.org/10.1097/01.TP.0000441090.39840.b0
  5. Alanine aminotransferase to hemoglobin ratio is an indicator for disease progression for hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization vol.37, pp.3, 2016, https://doi.org/10.1007/s13277-015-4082-y